Toshifumi Akizawa

Dr. Toshifumi Akizawa

1. Laboratory of Pharmacology, School of Medicine, Koch University, Nankoku 783-0047, Japan</br> 2. O-Force Co., Ltd., 3454 Irino Kuroshio-cho, Hata-gun, Kochi 789-1931, Japan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YUYusuke Ueba
Yusuke Ueba
TATakaaki Aratake
Takaaki Aratake
KOKen-Ichi Onodera
Ken-Ichi Onodera
YHYouichirou Higashi
Youichirou Higashi
THTomoya Hamada
Tomoya Hamada
MSMotoaki Saito
Motoaki Saito

1 June 2019 in Peptides
Verified
Journal Article
Closed access
RNRina Nakamura
Rina Nakamura
MKMotomi Konishi
Motomi Konishi
MTMasanari Taniguchi
Masanari Taniguchi
YHYusuke Hatakawa
Yusuke Hatakawa
Toshifumi AkizawaToshifumi Akizawa
Toshifumi Akizawa

19 April 2023 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
TAToshifumi Akizawa
Toshifumi Akizawa
MKMotomi Konishi
Motomi Konishi
YHYouichirou Higashi
Youichirou Higashi
MSMotoaki Saito
Motoaki Saito
Toshifumi AkizawaToshifumi Akizawa
Toshifumi Akizawa
Background: The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screened 22 kinds of 5-mer synthetic peptides derived from the Box A region of Tob1 protein to find a peptide effective against Aβ aggregation. Methods: A Thioflavin T (ThT) assay was performed to evaluate aggregation and screen aggregation inhibitors. Male ICR mice (6 weeks old) were administered saline, 9 nmol Aβ25-35, or a mixture of 9 nmol Aβ25-35 and 9 nmol GSGFK in the right lateral ventricle. Short-term spatial memory was assessed through Y-maze. Microglia cells (BV-)2 cells were plated on 24-well plates (4 × 104 cells/well) and incubated for 48 h, and then, the cells were treated with 0.01, 0.05, 0.1, 0.2, or 0.5 mM GSGFK. After incubation for 24 h, bead uptake was evaluated using a laser confocal microscope and Cytation 5. Results: We found two kinds of peptides, GSGNR and GSGFK, that were not only suppressed by aggregation of Aβ25-35 but also resolved the aggregated Aβ25-35. Results obtained from the Y-maze test on an Aβ25-35-induced AD model mouse indicated that GSGFK prevents the deficits in short-term memory induced by Aβ25-35. The effect of GSGFK on phagocytosis in BV-2 cells proved that GSGFK activates the phagocytic ability of microglia. Conclusions: In conclusion, 5-mer peptides prevent short-term memory deficit in Aβ25-35 induced AD model mouse by reducing the aggregated Aβ25-35. They may also upregulate the phagocytic ability of microglia, which makes 5-mer peptides suitable candidates as therapeutic drugs against AD.

23 September 2019 in Heliyon
Verified
Journal Article
Open access
PDF file
YHYusuke Hatakawa
Yusuke Hatakawa
RNRina Nakamura
Rina Nakamura
MKMotomi Konishi
Motomi Konishi
TSToshiyasu Sakane
Toshiyasu Sakane
MSMotoaki Saito
Motoaki Saito
Toshifumi AkizawaToshifumi Akizawa
Toshifumi Akizawa
We have recently reported about shorter proteolytic peptides termed Catalytide as general name. JAL-TA9 (YKGSGFRMI), a fragment peptide derived from Box A region of Tob1 protein, is the first Catalytide and cleaves Aβ42 and its fragment peptides. Herein, we demonstrate the enzymatic properties of ANA-TA9 corresponding region to JAL-TA9 in ANA/BTG3 protein. ANA-TA9 showed the auto-proteolytic activity and cleaved 3 kinds of synthetic fragment peptides derived from Aβ42, especially on the central region of Aβ42 with a serine protease like activity. Interestingly, 2 kinds of components, ANA-SA5 (SKGQA) and ANA-YA4 (YRMI), also showed similar proteolytic activity. These results indicate that ANA-TA9 is composed of two different Catalytides.

13 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YHYusuke Hatakawa
Yusuke Hatakawa
ATAkiko Tanaka
Akiko Tanaka
Tomoyuki FurubayashiTomoyuki Furubayashi
Tomoyuki Furubayashi
RNRina Nakamura
Rina Nakamura
MKMotomi Konishi
Motomi Konishi
TSToshiyasu Sakane
Toshiyasu Sakane
We have recently reported Catalytides (Catalytic peptides) JAL-TA9 (YKGSGFRMI) and ANA-TA9 (SKGQAYRMI), which are the first Catalytides found to cleave Aβ42. Although the Catalytides must be delivered to the brain parenchyma to treat Alzheimer’s disease, the blood–brain barrier (BBB) limits their entry into the brain from the systemic circulation. To avoid the BBB, the direct route from the nasal cavity to the brain was used in this study. The animal studies using rats and mice clarified that the plasma clearance of ANA-TA9 was more rapid than in vitro degradation in the plasma, whole blood, and the cerebrospinal fluid (CSF). The brain concentrations of ANA-TA9 were higher after nasal administration than those after intraperitoneal administration, despite a much lower plasma concentration after nasal administration, suggesting the direct delivery of ANA-TA9 to the brain from the nasal cavity. Similar findings were observed for its transport to CSF after nasal and intravenous administration. The concentration of ANA-TA9 in the olfactory bulb reached the peak at 5 min, whereas those in the frontal and occipital brains was 30 min, suggesting the sequential backward translocation of ANA-TA9 in the brain. In conclusion, ANA-TA9 was efficiently delivered to the brain by nasal application, as compared to other routes.

27 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
TAToshifumi Akizawa
Toshifumi Akizawa
Toshifumi AkizawaToshifumi Akizawa
Toshifumi Akizawa
MKMotomi Konishi
Motomi Konishi
We recently discovered JAL-TA9 (YKGSGFRMI), a short hydrolytic peptide that we termed a Catalytide. The catalytic center of JAL-TA9 was modeled using MM2 and MMFF94 parameters and identified as GSGFR. Additionally, a structure–activity relationship study showed that GSGYR cleaved Aβ11-29. Here, we developed a novel Catalytide in silico. Molecular dynamics simulations of GSGYR and RYGSG using MM2 and MMFF94 parameters suggested that both peptides may form catalytic triads and oxyanion holes. The hydrolytic potency of RYGSG was five times higher than that of GSGYR. Moreover, both peptides showed three common cleavage positions for Aβ11-29; namely, L17-V18, V18-F19, and E22-D23. The aggregation ratio analyzed by the thioflavin-T assay correlated well with proteolytic activity, suggesting that the aggregation of Aβ11-29 was suppressed by the cleavage reaction. Docking simulations with the carbonyl carbon of L17 or the carbonyl carbon of E22 in Aβ11-29 were conducted using the secondary structures of GSGYR and RYGSG. The distance between the hydroxyl group of serine and the carbonyl carbon of the two cleavage sites proved that RYGSG was closer to Aβ11-29 than to GSGYR. This study demonstrated that Catalytides are useful for understanding structure–activity relationships.